Research Article

Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway

Figure 2

Anlotinib inhibited MET to participate in the DDP resistance of NSCLC cells. (a) MET mRNA expression was detected by qRT-PCR in A549/DDP and H1299/DDP cells treated with or without anlotinib. (b) The p-MET/MET protein expression was examined by western blot analysis in A549/DDP and H1299/DDP cells treated with or without anlotinib. (c–g) A549/DDP and H1299/DDP cells were transfected with oe-MET and then treated with anlotinib and DDP. (c) MET mRNA expression was examined by qRT-PCR. (d) Western blot analysis was used to examine p-MET/MET protein expression. CCK8 assay (e), colony formation assay (f), and transwell assay (g) were used to assess cell viability, proliferation, migration, and invasion. , , and .